RELIS

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "RELIS" – news · newspapers · books · scholar · JSTOR (February 2018) (Learn how and when to remove this message) The topic of this article may not meet Wikipedia's notability guidelines for products and services. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "RELIS" – news · newspapers · books · scholar · JSTOR (February 2018) (Learn how and when to remove this message) (Learn how and when to remove this message)

Regional Medicines Information Centres (RELIS) (Norwegian: Regionale legemiddelinformasjonssentre) is a publicly funded information service about medical drugs for health professionals in Norway. RELIS was established to aid rational and proper medicines use through producer-independent drug information to health professionals. RELIS started its service at two centres in 1995, and has since 2001 been established at university hospitals in all four health regions of Norway. All the centres are tied to the clinical pharmacology departments at the university hospitals. RELIS has a question-answer service which aids health professionals in matters of medical drugs, often specific to an individual patient. The target group and users of the service is primarily medical doctors, but also pharmacists, dentists, nurses and midwives use the service.

RELIS is also responsible for an information service aided at pregnant and breastfeeding women called Trygg Mammamedisin ('Safe Mommy Medicine'). This service is accessible through its own website, and also by phone. It is open to the public and is confidential and free of charge.

Another important role for RELIS is pharmacovigilance. RELIS receives adverse side effect alerts submitted by health professionals, and RELIS then judges the course and causalities of each case, and sends a written reply to the person who submitted the message. The adverse side effect reports are then registered in a national adverse side effect database, in close cooperation with the Norwegian Medicines Agency. RELIS is financed by the Ministry of Health and Care Services.